We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Call for More Details in FDA Guidance on Assessing Pressor Effects
Drugmakers Call for More Details in FDA Guidance on Assessing Pressor Effects
FDA draft guidance on assessing a new drug’s impact on blood pressure does not adequately explain the agency’s thinking on the use of smaller clinical trials and should incorporate a more risk-based approach, according to comments from three leading drug sponsors.